Clinical Trials Logo
  1. Home
  2. Febrile Neutropenia
  3. NCT01450241

Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia

Febrile Neutropenia Clinical Trial

Official title:
Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia: Randomized-controlled Trial

Clinical Trial Summary

The purpose of this study is to determine whether short-course antibiotic therapy is safe and effective for the treatment of cancer patients with febrile neutropenia.

Clinical Trial Description

Febrile neutropenia remains a major cause of morbidity in solid cancer patients. There is an unresolved question regarding the appropriate duration of antibiotic treatment for patients with febrile neutropenia of unknown origin. Current guidelines recommend at least seven days of antibiotic treatment. Several studies have demonstrated the safety of early antibiotic discontinuation in patients with febrile neutropenia. We plan an open label randomized controlled trial to compare early antibiotic discontinuation to the accepted prolonged antibiotic treatment protocol ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01450241
Study type Interventional
Source Rabin Medical Center
Contact
Status Withdrawn
Phase N/A
Start date January 2012
Completion date January 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT03641131 - Ampholipad Real-World Data in Taiwan
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT03104595 - Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT02536599 - Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
Completed NCT02005783 - Study of Danggui Buxue Decoction in Preventing Neutropenia Phase 2
Recruiting NCT03449693 - Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia Phase 2
Recruiting NCT05149547 - mNGS Versus Blood Culture in FN
Recruiting NCT05584930 - Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN) N/A
Completed NCT04134429 - Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Recruiting NCT01684189 - Registry of Febrile Neutropenia and Invasive Fungal Infections N/A
Completed NCT00462878 - Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation N/A
Completed NCT00035425 - Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection Phase 3
Recruiting NCT04948463 - Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia Phase 4
Recruiting NCT03740464 - Long-acting G-CSF for Febrile Neutropenia Phase 3
Not yet recruiting NCT06116734 - Lapelga vs Gastrofil Phase 3
Completed NCT00503854 - Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Terminated NCT02732327 - Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer Phase 2
Completed NCT01114165 - Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Phase 4